Employer record · Burlington, MA · FY2022–FY2026
PharmaEssentia USA Corporation
- Certified LCAs
- 3
- FY2024–FY2026
- USCIS approvals
- 2
- 1 new employment
- Denial rate
- 0.0%
- FY2024–FY2026
- Median wage offered
- $165k
- certified LCAs
Does PharmaEssentia USA Corporation sponsor H-1B visas?
Yes — by its record, PharmaEssentia USA Corporation is a small-scale H-1B sponsor: it filed 3 certified Labor Condition Applications (LCAs) in FY2024–FY2026 and received 2 USCIS H-1B petition approvals (1 for new employment). Its latest certified LCA in our data was decided Jun 1, 2026. Past filings are history, not a promise: they do not mean the employer will sponsor you or a given role.
Top sponsors in Massachusetts →Scientific research and development sponsors →Sponsors based in Burlington →
Filings by fiscal year
Certified LCAs per U.S. government fiscal year (Oct–Sep) — 4 since FY2020; the slim bar is USCIS petition approvals (new + continuing), the bottom row their approval rate.
| Fiscal year | certified LCAs | USCIS approvals | Approval rate |
|---|---|---|---|
| FY22 | 1 | 1 | 100% |
| FY26 | 3 | 2 | 100% |
Occupations sponsored
| Occupation (SOC) | LCAs | Median wage |
|---|---|---|
| Natural Sciences Managers 11-9121 | 1 | $175k |
| Management Analysts 13-1111 | 1 | $165k |
| Market Research Analysts and Marketing Specialists 13-1161 | 1 | $85k |
Most-filed job titles
- Manager, Corporate Strategy2$170k
- Investor Relations & Corporate Communications Specialist1$85k
LCAs per title and median wage offered.
Where the jobs were
- Massachusetts2 LCAs
- California1 LCAs
We haven't indexed PharmaEssentia USA's jobs yet
We read jobs straight from employers' own career sites and haven't added PharmaEssentia USA's yet. Its H-1B record on this page comes from public DOL and USCIS data and is not affected.
Also filed as
- PharmaEssentia USA Corporation (LCA)
- PHARMAESSENTIA USA CORPORATION (USCIS)
PharmaEssentia USA Corporation H-1B: questions people ask
Does PharmaEssentia USA Corporation sponsor H-1B visas?
Yes — by its record, PharmaEssentia USA Corporation is a small-scale H-1B sponsor: it filed 3 certified Labor Condition Applications (LCAs) in FY2024–FY2026 and received 2 USCIS H-1B petition approvals (1 for new employment). Its latest certified LCA in our data was decided Jun 1, 2026. Past filings are history, not a promise: they do not mean the employer will sponsor you or a given role.
Is PharmaEssentia USA Corporation still sponsoring H-1B in 2026?
PharmaEssentia USA Corporation had 3 certified LCAs in FY2026 (Oct 2025–Sep 2026), more than the 0 in FY2025. The latest one in our data was decided Jun 1, 2026. An LCA is filed before a petition, so it shows recent intent to hire on H-1B, not a hire.
How many H-1B petitions does PharmaEssentia USA Corporation get approved?
USCIS recorded 2 approvals (1 for new employment, the rest continuing employment such as extensions and transfers) and 0 denials for PharmaEssentia USA Corporation in FY2024–FY2026 — a denial rate of 0.0%. Source: USCIS H-1B Employer Data Hub (first decisions).
What is the H-1B salary at PharmaEssentia USA Corporation?
The median wage offered on PharmaEssentia USA Corporation's certified LCAs in FY2024–FY2026 was $165k a year. By job title: Manager, Corporate Strategy $170k (2 LCAs) and Investor Relations & Corporate Communications Specialist $85k (1 LCAs). LCA wages are the pay the employer attested to; actual pay can be higher.
Which jobs does PharmaEssentia USA Corporation sponsor for H-1B?
Its certified LCAs in FY2024–FY2026 were mostly for Natural Sciences Managers (1), Management Analysts (1) and Market Research Analysts and Marketing Specialists (1).
Where are PharmaEssentia USA Corporation's H-1B jobs?
By worksite on its certified LCAs (FY2024–FY2026): Massachusetts (2) and California (1).
Is PharmaEssentia USA Corporation an H-1B dependent employer?
No — its recent LCAs do not declare it H-1B dependent.
Does PharmaEssentia USA Corporation have open jobs?
We read jobs straight from employers' own career sites and haven't added PharmaEssentia USA's yet.